Abstract
Antidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2, KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad. These genes represent good candidates for the definition of a genetic pro-arrhythmic profile. A genetic analysis of these targets is provided and their possible pathophysiological role in arrhythmias is discussed. Special attention is devoted to the interactions between these genes and new generation antidepressants and antipsychotics. A list of relevant rare mutations within the selected genes is presented, together with a complete list of Tag SNPs covering the whole genetic sequence. The aim of this paper is to define a part of the genetic framework responsible for the proarrhythmic effects of antidepressants and antipsychotics. The selected variants, both mutations and polymorphisms, may help in defining a next-to-come genetic assessment to be performed before drug prescription in order to improve drug safety.
Keywords: Pharmacogenetics, arrhythmia, cardiotoxicity, adverse events, antipsychotics, antidepressants, long QT
Current Medicinal Chemistry
Title: Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Volume: 15 Issue: 24
Author(s): Antonio Drago, Fabrizio De Ponti, Giuseppe Boriani, Diana De Ronchi and Alessandro Serretti
Affiliation:
Keywords: Pharmacogenetics, arrhythmia, cardiotoxicity, adverse events, antipsychotics, antidepressants, long QT
Abstract: Antidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2, KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad. These genes represent good candidates for the definition of a genetic pro-arrhythmic profile. A genetic analysis of these targets is provided and their possible pathophysiological role in arrhythmias is discussed. Special attention is devoted to the interactions between these genes and new generation antidepressants and antipsychotics. A list of relevant rare mutations within the selected genes is presented, together with a complete list of Tag SNPs covering the whole genetic sequence. The aim of this paper is to define a part of the genetic framework responsible for the proarrhythmic effects of antidepressants and antipsychotics. The selected variants, both mutations and polymorphisms, may help in defining a next-to-come genetic assessment to be performed before drug prescription in order to improve drug safety.
Export Options
About this article
Cite this article as:
Drago Antonio, De Ponti Fabrizio, Boriani Giuseppe, De Ronchi Diana and Serretti Alessandro, Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia, Current Medicinal Chemistry 2008; 15 (24) . https://dx.doi.org/10.2174/092986708785909058
DOI https://dx.doi.org/10.2174/092986708785909058 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Editorial (Thematic Issue: Surface Electrocardiogram Remains Alive in the XXI Century)
Current Cardiology Reviews Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry New Electrocardiographic Features in Brugada Syndrome
Current Cardiology Reviews Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine The Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia
Current Cardiology Reviews Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Human Cardiac Ryanodine Receptor: Preparation, Crystallization and Preliminary X-ray Analysis of the N-terminal Region
Protein & Peptide Letters MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA